Docoh
Loading...

HUMA Humacyte

News

From Benzinga Pro
Humacyte Presents Preclinical Results Of Small-Diameter HAV For Use As A BTT Shunt In Pediatric Heart Disease At American Heart Association's Scientific Sessions 2021
16 Nov 21
Biotech, News, Events, General
Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced positive results from a preclinical study
Humacyte Highlights Presentation Of 12-Month Data From Human Acellular Vessel Produced Using Commercial-Scale Manufacturing System
15 Nov 21
News
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency
Humacyte Q3 EPS $(0.72) Up From $(3.07) YoY, Grant Sales $241.00K Down From $914.00K YoY
12 Nov 21
Earnings, News
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.72) per share. This is a 76.55 percent increase over losses of $(3.07) per share from the same period last year. The company reported $241.00 thousand in sales
64 Biggest Movers From Yesterday
2 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the company filed a mixed shelf offering on Friday after the close.
Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
29 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Cowen & Co. Initiates Coverage On Humacyte with Outperform Rating, Announces Price Target of $17
29 Oct 21
News, Price Target, Initiation, Analyst Ratings
Cowen & Co. analyst Joshua Jennings initiates coverage on Humacyte (NASDAQ:HUMA) with a Outperform rating and announces Price Target of $17.
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
24 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Oppenheimer Initiates Coverage On Humacyte with Outperform Rating, Announces Price Target of $16
24 Sep 21
News, Price Target, Initiation, Analyst Ratings
Oppenheimer analyst Suraj Kalia initiates coverage on Humacyte (NASDAQ:HUMA) with a Outperform rating and announces Price Target of $16.
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
22 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
BTIG Initiates Coverage On Humacyte with Buy Rating, Announces Price Target of $19
22 Sep 21
News, Price Target, Initiation, Analyst Ratings
BTIG analyst Ryan Zimmerman initiates coverage on Humacyte (NASDAQ:HUMA) with a Buy rating and announces Price Target of $19.
Humacyte Highlights List Of Sept. Presentations, Including Upcoming Events On Sept. 17, 23, 24
17 Sep 21
News, Events
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021
16 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Piper Sandler Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $17
16 Sep 21
News, Price Target, Initiation, Analyst Ratings
Piper Sandler analyst Matt O'Brien initiates coverage on Humacyte (NASDAQ:HUMA) with a Overweight rating and announces Price Target of $17.
72 Biggest Movers From Yesterday
14 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
53 Biggest Movers From Friday
7 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform.

Press releases

From Benzinga Pro
Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association's Scientific Sessions 2021
16 Nov 21
Health Care, Press Releases
-- Patency and host cell remodeling of the HAV were observed in all study implants – -- Preclinical study is one component of Humacyte's expansion of the testing of the HAV in a broader cardiac bypass surgery
Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System
15 Nov 21
Health Care, Press Releases, General
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights
12 Nov 21
Earnings, Press Releases
-- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds -- -- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and
Humacyte Leadership to Present at Multiple Scientific Events in November
8 Nov 21
News, Press Releases
DURHAM, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today
Humacyte Leadership to Present at Seven Scientific and Industry Events in October
5 Oct 21
News, Press Releases
DURHAM, N.C., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today
Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengineered Human Tissue Platform
20 Sep 21
News, Health Care, Legal, Press Releases
Patent estate also expanded by the issuance of 23 additional patents in international marketsHumacyte now owns or licenses 119 patents covering its proprietary platform DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE)
Humacyte Leadership to Present at Five Scientific Events in September
17 Sep 21
Health Care, Press Releases
DURHAM, N.C., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today